Outcomes in relapsed/refractory diffuse large B-cell lymphoma in an Asian tertiary cancer center: real-world interventions as benchmark for novel therapy

作者：Nicole-Ann Lim, Yang Sun, Jing Yuan Tan, Robert Lim, Yeh Hong Tan, L.C.K. Ng, Francesca Lim, Yeow Tee Goh, Joshua Tian Ming Hoe, Jianbang Chiang, Esther Wei Yin Chang, Eileen Poon, N. Somasundaram, M. Tao, Soon Thye Lim, Estefania Mulvihill, A. Hanna-Elias, Jason Yongsheng Chan · 发表于：ESMO Real World Data and Digital Oncology · 年份：2025 · DOI：10.1016/j.esmorw.2025.100195 · 被引用次数：1 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Chronic Lymphocytic Leukemia Research

Recent advances have led to the approval of several new therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, real-world data for treatment patterns and outcomes in R/R DLBCL in Asian countries are lacking, limiting the benchmarking of novel treatments. We conducted a retrospective single-center cohort study including 227 patients with R/R DLBCL diagnosed from 2010 to 2022. Outcomes including progression-free survival (PFS) and overall survival (OS) were assessed. In the overall cohort, median OS was 13.5 months and 5-year OS was 29.8% from the time of first relapse. Median time to first relapse from completion of first-line immunochemotherapy was 7.03 months (range 0-148.4 months). Time to first relapse was significantly associated with OS outcomes. Patients who had earlier relapse, defined as 12 months or less from first-line treatment, had worse OS at 8.6 months, as compared with patients who relapsed >12 months after first-line treatment, who had OS of 34.2 months (hazard ratio 1.73, 95% confidence interval 1.26-2.37, P = 0.007). Median PFS was 3.2 months as compared with 15.3 months, respectively. The majority ( n = 121, 53.3%) were transplant-ineligible and only 44 (19.4%) were transplanted. The median PFS for non-transplant recipients was 3.5 months versus 34.4 months for transplant recipients. The median OS for non-transplant recipients was 8.5 months versus 114.1 months for transplant recipients. Poor outcomes remain for patients with ...